Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Shares Shorted: Short Interest Up 715.0% in September

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totaling 271,866 shares, a growth of 715.0% from the August 31st total of 33,356 shares. Based on an average daily volume of 20,006,870 shares, the days-to-cover ratio is currently 0.0 days. Currently, 26.5% of the shares of the stock are sold short.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

An institutional investor recently bought a new stake in Biodexa Pharmaceuticals stock. Sabby Management LLC purchased a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals accounts for approximately 0.6% of Sabby Management LLC’s holdings, making the stock its 10th largest holding. Sabby Management LLC owned approximately 28.04% of Biodexa Pharmaceuticals as of its most recent SEC filing. Institutional investors own 17.51% of the company’s stock.

Biodexa Pharmaceuticals Price Performance

Shares of BDRX opened at $0.68 on Friday. The firm has a 50-day moving average price of $1.23 and a 200 day moving average price of $2.61. Biodexa Pharmaceuticals has a 12-month low of $0.61 and a 12-month high of $59.40.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, September 14th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company combines drug candidates with proprietary delivery technologies intended to improve how therapies are administered, distributed, or released in the body.

Biodexa’s pipeline has included MTX110, a liquid formulation of the cancer medicine panobinostat being investigated for direct administration into brain tumors, including diffuse midline glioma.